Recently, cancer immunotherapy targeting cytotoxic T cells and immunoescape signaling of tumor cells has changed the direction of cancer treatment; however, some patients still experience serious immunological side effects and poor treatment response, and many studies have focused on ways to overcome the irreversible dysfunction of cytotoxic CD8 T cell activity [43–45]. The gene discussed is CD8A; the disease is neoplasm.